Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Timothy M. Klein
Observed names:
Klein, Timothy M.,
T. Klein,
T.M. Klein,
Timothy Klein,
Timothy M Klein
Institution:
Medical Decision Modeling (United States)
Observed institutions:
University of East Anglia,
University of Cape Town,
Norwich Research Park,
Medical Decision Modeling (United States),
Institute of Infectious Disease and Molecular Medicine,
University of the Western Cape
show all 6
ORCID:
0000-0002-4428-6181
Observed ORCID:
0000-0002-4428-6181
OpenAlex ID:
A5058526962
The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden
2012
·
Daniel R Murphy
, Lee J Smolen
, et al.
·
BMC Musculoskeletal Disorders
·
49
PDF
Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma
2023
·
Sundar Jagannath
, Nedra Joseph
, et al.
·
Oncology and Therapy
·
41
PDF
Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States
2012
·
Haya Ascher-Svanum
, Nicolas M. Furiak
, et al.
·
Journal of Medical Economics
·
37
PDF
Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives
2016
·
Ronald C. Wielage
, Sinem Perk
, et al.
·
Journal of Medical Economics
·
33
PDF
Cultivation of ammonia-oxidising archaea on solid medium
2022
·
Timothy Klein
, Lianna Poghosyan
, et al.
·
FEMS Microbiology Letters
·
26
PDF
Assessing the Cost-effectiveness of a Hypothetical Disease-modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease
2022
·
Malaz Boustani
, Erin G. Doty
, et al.
·
Clinical Therapeutics
·
17
PDF
Using Common Random Numbers in Health Care Cost‐Effectiveness Simulation Modeling
2013
·
Daniel R. Murphy
, Robert W. Klein
, et al.
·
Health Services Research
·
17
Modeling screening, prevention, and delaying of Alzheimer's disease: an early-stage decision analytic model
2010
·
Nicolas M Furiak
, Robert W Klein
, et al.
·
BMC Medical Informatics and Decision Making
·
15
PDF
Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder
2016
·
Sinem Perk
, Ronald C. Wielage
, et al.
·
Journal of Managed Care & Specialty Pharmacy
·
13
PDF
Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer’s Disease in the United States
2024
·
Malaz Boustani
, Erin G. Doty
, et al.
·
Neurology and Therapy
·
12
PDF
Total Car-T Cost of Care Beyond the Price of Car-T Cell Therapy in Patients with Multiple Myeloma
2021
·
Sundar Jagannath
, Nedra Joseph
, et al.
·
Blood
·
10
Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States
2022
·
Jing Voon Chen
, Timothy M. Klein
, et al.
·
Journal of Medical Economics
·
8
Budget impact analysis of insulin therapies and associated delivery systems
2012
·
Lauren J. Lee
, Lee J. Smolen
, et al.
·
American Journal of Health-System Pharmacy
·
8
Screening and treatment for Alzheimer's disease: Predicting population‐level outcomes
2012
·
Nicolas M. Furiak
, Kristin Kahle‐Wrobleski
, et al.
·
Alzheimer s & Dementia
·
6
Replication Of A Published Markov Chronic Migraine Cost-Effectiveness Analysis Model For Purposes Of Early Phase Adaptation And Expansion
2015
·
L.J. Smolen
, T.M. Klein
, et al.
·
Value in Health
·
5
Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder
2016
·
Sinem Perk
, Ronald C. Wielage
, et al.
·
Journal of Managed Care & Specialty Pharmacy
·
4
Draft Genome Sequences of Three Bacillus Species from South African Marine Sponges
2016
·
Leonardo Joaquim van Zyl
, Relebohile Matobole
, et al.
·
Genome Announcements
·
3
PDF
PRM145 A Maximum Likelihood Simulation Technique for Estimating Adverse Event Rates From Published Trials
2012
·
R.C. Wielage
, G.P. Samsa
, et al.
·
Value in Health
·
3
Pnd21 10-year Cost-effectiveness Analyses of Fremanezumab as Preventive Treatment in Chronic and Episodic Migraine
2019
·
L. Smolen
, S.K. Gandhi
, et al.
·
Value in Health
·
2
IC‐P‐026: Biomarker screening for Alzheimer's disease: When to screen and how often?
2009
·
Kristin Kahle‐Wrobleski
, Nick Furiak
, et al.
·
Alzheimer s & Dementia
·
2
PDF
10-Year Cost-effectiveness Analyses of Fremanezumab Compared to Erenumab as Preventive Treatment in Episodic Migraine for Patients With Inadequate Response to Prior Preventive Treatments (4491)
2020
·
Lee Smolen
, Joshua Cohen
, et al.
·
Neurology
·
1
Pcn131 Cost Effectiveness of Pemetrexed in Combination With Pembrolizumab and Platinum Chemotherapy (pem+pembro+plat), for Initial Treatment of Patients With Metastatic Non-squamous (nsq) Non-small Cell Lung Cancer (nsclc) in the U.s.
2019
·
H. Aggarwal
, C.E. Muehlenbein
, et al.
·
Value in Health
·
1
Regulation of HIV receptor expression in cervical epithelial cells by Gram-negative bacterial lipopolysaccharide
2014
·
Kurt J Sales
, Timothy Klein
, et al.
·
South African Medical Journal
·
1
PDF
PUK17 Economic Benefits of Slowing Progress to End Stage Renal Disease (ESRD) in Patients with Diabetes-Related Chronic Kidney Disease (DKD), Compared with Standard of Care (SOC)
2012
·
L.J. Smolen
, T.M. Klein
, et al.
·
Value in Health
·
1
P2‐042: Biomarker screening for Alzheimer's Disease: When to screen and how often?
2009
·
Kristin Kahle‐Wrobleski
, Nick Furiak
, et al.
·
Alzheimer s & Dementia
·
1
Show more works
View as search
Works count:
38
Citation count:
316
H-index:
10
I10-index:
11
Year
Topic
Type
